1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag

Manuscript with complete study results from migraine study submitted to scientific journal

The complete study results from Chordate Medical's migraine study 007 have today been submitted as a manuscript for publication in one of the three most prominent journals within the migraine field.

“This is a pivotal step, and once the scientific article is published, it will be a valuable tool for the company in marketing and sales efforts. Additionally, the article will be an important basis in upcoming reimbursement processes," says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical will announce when the authors have received approval for publication in the journal in question.

The final results from Chordate Medical's PM007 study demonstrate that the company's migraine treatment, K.O.S, exhibits a significant reduction in the number of headache days and migraine days in adult patients with moderate to severe chronic migraine. The results also show that K.O.S maintains a sustained therapeutic effect and is well-tolerated, with few unexpected side effects. This sets apart the unique treatment, which is non-pharmaceutical, from other preventative treatments in the market, also due to its favorable side effect profile.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Manuscript with complete study results from migraine study submitted to scientific journal

Datum 2023-08-21, kl 14:53
Källa MFN
Bifogade filer
Manuscript with complete study results from migraine study submitted to scientific journal
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!